The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid improved regulatory clarity for gene therapies, SeekingAlpha upgraded REGENXBIO (RGNX) to 'Strong Buy'. The upgrade follows the FDA's course reversal on rare disease treatments, supporting the resubmission of the NAVSUNLI Biologics License Application in Q3 2026 without requiring new clinical studies.
NAVSUNLI (RGX-121) is a gene therapy for rare MPS II disease, and REGENXBIO's pipeline also includes RGX-202 for Duchenne muscular dystrophy and sura-vec for wet age-related macular degeneration, providing additional catalysts through 2027 according to analysts. A potential approval could strengthen the company's position in the gene therapy market.
Sign in to access this content
Sign InOn the trading front, RGNX shares have not yet traded on June 28, but the upgrade may support positive momentum. No near-term economic events impact the sector, and the focus remains on the NAVSUNLI BLA submission in Q3 2026 as the next major catalyst for the stock.